Advertising


News

Another potential long COVID treatment ruled out


Chelsea Heaney


14/06/2024 2:42:12 PM

A COVID-19 antiviral has been shown to be ineffective at treating the condition, as doctors continue to be left with few options.

Blister pack of Paxlovid
New research shows a two-week course of nirmatrelvir and ritonavir is no better than placebo at resolving long COVID symptoms. (Image: AAP)

The search is still on for an effective long COVID treatment, after an international trial found nirmatrelvir and ritonavir (sold as Paxlovid) did not improve patient outcomes.
 
The study, from Stanford Medicine, looked at the use of Paxlovid in 155 predominately vaccinated patients with long COVID symptoms lasting at least three months, with two-thirds of the group given a two-week course of Paxlovid and the other third given a placebo.
 
The researchers say there was no difference in the severity of symptoms for those taking Paxlovid compared to the placebo group, suggesting that although the drug is safe, it is not worth using as a long COVID treatment.
 
Infectious disease physician and microbiologist Professor Paul Griffin told newsGP while representing another treatment people have hoped could help, the lack of efficacy is not surprising.
 
‘We know the oral antivirals do help reduce the chance of people progressing in severe disease for those who are higher risk, but that’s particularly dependent on them getting it early,’ he said.
 
‘That impact falls away even after three days, let alone using it down the track for people who literally have long COVID.
 
‘We obviously would very much like therapies that help with long COVID but it seems that oral antivirals are probably not that type of treatment.’
 
However, GP and long COVID clinic director Dr Bernard Shiu believes a month-long study may have been more insightful and potentially delivered better results.
 
‘Some studies are showing a longer course [up to 30 days] of antiviral may be needed to show the benefit,’ he told newsGP.
 
‘More research will be needed to focus on who we give the antiviral to and why.’
 
As GPs are left with few options, Professor Griffin says patients are becoming increasing desperate.
 
‘Many people, they struggle to find a physician who will listen to them and be able to even try to help them, and even when we hear them, there is obviously still very little we can do at the moment,’ he said.
 
‘So, they’ve gone overseas and tried all sorts of things that don’t really have much of an evidence base.’
 
GP and lecturer Dr Ken McCroary, who has led long COVID research, said the Stanford study reinforces that GPs should remind patients that vaccination is the only preventive treatment for long COVID.
 
‘Particularly for the elderly and those at the most risk, they need to continue to get their injections,’ he told newsGP.
 
Even though the study generated negative results, Professor Griffin also said the research is still useful.
 
‘People might be disappointed that it hasn’t demonstrated an effect for something that some people might be optimistic for, [but] this is really useful information,’ he said.
 
‘Now [we] can hopefully ensure we redirect our efforts to things that might be more likely to work.’
 
Log in below to join the conversation.



antivirals COVID-19 long COVID nirmatrelvir Paxlovid placebo ritonavir


newsGP weekly poll Would you be willing to provide a firearms health assessment for your patient?
 
8%
 
82%
 
9%
Related




newsGP weekly poll Would you be willing to provide a firearms health assessment for your patient?

Advertising

Advertising


Login to comment

Dr Dhara Prathmesh Contractor   18/06/2024 6:59:41 AM

Millions wasted to help pharmaceutical availability of this drug to patients.
Medicare PBS health funds hoping will acknowledge this study soon and will likely cease $millions of funding wasted towards pharmaceutical benefits for these drugs.
Each box of paxlovid above $1k!

Daily cost of living and inflation statements and political advertising is only costing mental health pressures in the community. Advertising of what more funds will be allocated where !! Everyday crisis and funds allocation.
But this is after all tax payers money. Countries funds.
Lets us it right!

How can we get together and help each other and live well supporting each other on the TV will help us all. Help with resources we have. Preserve the resources we have.


Dr Julia Elisa Gan   18/06/2024 7:32:40 AM

GPs continuallly remind patients that vaccination is the only preventive treatment for long Covid. Covid vaccine availability in Australia is limited to Pfizer and Moderna vaccines. Some patients are unable to have these for medical reasons. A full suite of Covid vaccines is not available in Australia. Novavax JN.1 vaccine will be avaiable in the USA and overseas from August 2024. No sign of action yet from TGA on this!